araag2/HINT huggingface dataset:
Clinical trial NCT00108485 (phase 3, status: terminated)
Conditions: diabetes mellitus, type 2, kidney failure, chronic, hyperlipidemia
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, N99.0, I13.0, I13.10, I13.11, I13.2, E78.2, E78.49, E78.5
Drugs: extended release niacin
SMILES: OC(=O)C1=CN=CC=C1
Reason stopped: 
    unable to recruit sufficient study subjects
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Diagnosis of chronic kidney disease stage 2 or 3 with an estimated GFR of 30-89 ml/min
             using the four variable MDRD (Modification of Diet in Renal Disease Study Group)
             formula

          -  Presence of microalbuminuria or proteinuria less than 3.5 g/d

          -  Diagnosis of hyperlipidemia currently treated with a "statin" drug

        Exclusion Criteria:

          -  Not meeting inclusion criteria

          -  HDL-C > 40 mg/dL for men, > 50 mg/dL for women

          -  TG (triglycerides) < 150 mg/dL and > 800 mg/dL

          -  Documented intolerance to Niaspan or Aspirin

          -  Treatment with other lipid-lowering agents (fibrates, BAS [bile acid sequestrants], or
             ezetimibe)

          -  Elevated transaminases (AST or ALT >1.3 x ULN)

          -  Unstable type 2 diabetes (FBG >200 mg/dL or HbA1c >9.5%)

          -  Known seropositivity for Hepatitis B, C, or HIV

          -  Documented history of malignancy

          -  Age < 18 years

          -  Pregnant women or nursing mothers

          -  Inability to give informed consent

          -  Start or change in "statin" dose < 2 months ago
Clinical trial NCT01471171 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium bromide, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult male and female patients aged ≥ 40 with stable moderate to severe COPD (Global
             Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines).

          -  Post-salbutamol Forced Expiratory Volume in one second(FEV1) < 80% and ≥ 30% of
             predicted normal value and Post-salbutamol FEV1/Forced Vital Capacity (FVC) < 70%.

          -  Current or ex-smokers of ≥ 10 pack-years

          -  Functional residual capacity (FRC) measured by body plethysmography at Screening Visit
             ≥ 120% of predicted value

        Exclusion Criteria:

          -  History or current diagnosis of asthma

          -  Signs of an exacerbation within 6 weeks ( or 3 months if results in hospitalisation)
             prior to the screening visit or during the run-in period.

          -  Clinically significant respiratory and/or cardiovascular conditions or laboratory
             abnormalities.

          -  Conditions where the use of anticholinergic drugs is contraindicated, such as known
             symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.

          -  Patients with an oxygen saturation < 85% during cycle exercise on room air at
             Screening Visit, Run- in Visit and Visit 1.

          -  Contra-indications of cardiopulmonary exercise testing.

          -  Patient who in the investigator's opinion will need to start a pulmonary
             rehabilitation program during the study and/or patients who have just started/finished
             pulmonary rehabilitation at least 3 months prior to the Screening Visit.
Clinical trial NCT00140751 (phase 3, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: lopinavir/ritonavir (drug)
SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age > or = 18 years

          -  Confirmed HIV-1 seropositivity

          -  Antiretroviral treatment stable since 3 months at least

          -  HIV-1 ARN load < 50 copies/mL since 6 months at least

          -  Signed consent form

          -  No history of treatment failure (= viral load > 1000 copies/mL) including a protease
             inhibitor

          -  No opportunistic infection in the previous 6 months

        Exclusion Criteria:

          -  Neutrophils < 750/mm3

          -  Hemoglobin < 8 g/dL

          -  Platelets < 60,000/mm3

          -  Creatinin > 150 micromoles/L

          -  SGOT > 5 NUL (Normal Upper Limit)

          -  SGPT > 5 NUL

          -  Current IL-2 treatment

          -  HBV infection treated or not by lamivudine or tenofovir

          -  Pregnancy or feeding

          -  Enrollment in another study not compliant with KALESOLO Study group assignment
Clinical trial NCT00690638 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: phx1149t, phx1149t, placebo
SMILES: OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]1CCNC1, OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]1CCNC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus, drug naïve or willing to wash-out from existing oral therapy

          -  BMI 25 to 48 kg/m2, inclusive

          -  HbA1c 7.0% - 10.0%, inclusive

          -  Age 18 to 75 years, inclusive

        Exclusion Criteria:

          -  Currently on 3 or more oral antidiabetic drugs or insulin.

          -  Type 1 diabetes mellitus
Clinical trial NCT01137474 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, placebo-matching dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Key inclusion criteria

          -  Participants willing and able to give signed and written informed consent

          -  Males and females, aged 18 to 89 years, who have type 2 diabetes with inadequate
             glycemic control (hemoglobin A1c between 7% and 10.5%) and uncontrolled hypertension
             (seated systolic blood pressure of 140 to 165 mm Hg and seated diastolic blood
             pressure 85 to 105 mm Hg)

          -  Mean 24-hour BP>=130/80 mmHg determined by ABPM

          -  Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks (12 weeks for
             thiazolidinedione) or a stable daily dose of insulin as monotherapy or in combination
             with another OAD, for 8 weeks, and a stable dose of an angiotensin-converting enzyme
             inhibitor or angiotensin-receptor blocker for at least 4 weeks

          -  C-peptide level ≥0.8 ng/mL

          -  Body mass index ≤ 45.0 kg/m^2

        Key exclusion criteria

          -  Aspartate aminotransferase or alanine aminotransferase level >3*upper limit of normal
             (ULN)

          -  Serum total bilirubin level >1.5*ULN

          -  Serum creatinine ≥2.0 mg/dL unless subject was on metformin, where exclusionary limits
             were serum creatinine ≥1.50 mg/dL for men and ≥1.40 mg/dL for women

          -  Estimated creatinine clearance of <60 mL/min

          -  Hemoglobin ≤10.0 g/dL for men and ≤9.0 g/dL for women

          -  Creatine kinase >3*ULN

          -  Positive for hepatitis B surface antigen

          -  Positive for antihepatitis C virus antibody

          -  Abnormal free T4 value

          -  History of diabetes insipidus

          -  Symptoms of poorly controlled diabetes that would preclude participation in this
             trial, including but not limited to, marked polyuria and polydipsia with greater than
             10% weight loss during the 3 months prior to enrollment.

          -  History of diabetic ketoacidosis or hyperosmolar nonketotic coma

          -  History of malignant and accelerated hypertension

          -  Known or suspected secondary hypertension

          -  Any of the following within 6 months of enrollment visit:

               -  Myocardial infarction

               -  Cardiac surgery or revascularization (coronary artery bypass surgery
                  /percutaneous transluminal coronary angioplasty)

               -  Unstable angina

               -  Unstable congestive heart disease or New York Heart Association Class III or IV

               -  Transient ischemic attack or significant cerebrovascular disease

               -  Unstable or previously undiagnosed arrhythmia
Clinical trial NCT01057628 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ipragliflozin, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients for at least 12 weeks

          -  HbA1c value between 7.0 and 10.0%

          -  Body Mass Index (BMI) 20.0 - 45.0 kg/m2

          -  Investigator adjudicates that a subject is able to discontinue currently taking
             hypoglycemic agents safely during treatment

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Proteinuria (albumin/creatinine ratio > 300mg/g)

          -  Dysuria and/or urinary tract infection, genital infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases
Clinical trial NCT01313624 (phase 3, status: completed)
Conditions: bronchiectasis
ICD codes: J47.9, Q33.4, J47.1, J47.0
Drugs: azli, placebo
SMILES: C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male/Female 18 years or older with non-CF bronchiectasis

          -  Chronic sputum production on most days

          -  Positive sputum culture for gram-negative organisms

          -  Must have met lung function requirements

        Exclusion Criteria:

          -  History of CF

          -  Hospitalized within 14 days prior to joining the study

          -  Previous exposure to AZLI

          -  Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study

          -  Must have met liver and kidney function requirements

          -  Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with
             activity and at night was allowed)

          -  Treatment for nontuberculous mycobacteria infection or active mycobacterium
             tuberculosis infection within 1 year of enrollment

          -  Other serious medical conditions.
Clinical trial NCT00158522 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: pegylated interferon alpha2a
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Acute hepatitis C:(1)ALT over 3x normal values ; IgM anti-HAV, IgM anti-HBc negative
             antibody ; negative HCV antibodies (3rd generation ELISA) and positive HCV PCR at
             first presentation, or, (2)ALT over 4x normal values ; IgM anti-HAV, IgM anti-HBc,
             CMV, EBV and toxoplasmoses negative antibody and negative HEV PCR ; Positive HCV
             antibodies (3rd generation ELISA) and positive HCV PCR at first presentation ; a clear
             history of exposure within 2 months prior the time of diagnosis ; no exposure to
             hepatotoxic drug or pesticide within 2 weeks prior the time of diagnosis

          -  Patients without chronic liver disease

          -  HBsAg negative

          -  Hemoglobin over or equal to 11g/dl

          -  Leucocytes over or equal to 3000/mm3

          -  Polynuclear neutrophils over or equal to 1500/mm3

          -  Platelets over or equal to 100 000/mm3

          -  Blood creatinin less or equal to 150 micromol/l

          -  Blood uric acid within the normal limits of the investigating center

          -  Normal TSH

          -  Antinuclear antibodies < 1/160

          -  Fasting blood sugar 70-115 mg/dl ; if glucose intolerance or diabetes, HbA1C less or
             equal to 8,5%

          -  Normal ophthalmologic examination for all patients

          -  Effective contraception during the treatment period.

          -  No breastfeeding during the study period

          -  Signed informed consent

        Exclusion Criteria:

          -  Co-infection with hepatitis B (positive HBs antigen)

          -  Hemochromatosis

          -  Alpha-1 anti-trypsin deficiency

          -  Wilson disease

          -  Alcoholism-related liver disease

          -  Gilbert disease

          -  Liver cirrhosis

          -  Hepatocellular carcinoma.

          -  Alcohol intake over 50g/day for males and 40 g/day for females

          -  Intravenous drug use

          -  Psychiatric disease: history of severe nervous breakdown or severe psychiatric
             diseases such as major psychosis, suicidal ideas, suicide attempts…

          -  Epilepsy

          -  Auto-immune disease

          -  Heart disease in the six months preceding enrolment - patients with significant
             changes at EKG

          -  Uncontrolled diabetes

          -  Chronic respiratory insufficiency with hypoxemia under 10 kPa

          -  Medical or surgical condition non-stabilized, with life expectancy lower than two
             years

          -  Pregnancy or breastfeeding

          -  Unavailability for regular follow-up during the study
Clinical trial NCT00549562 (phase 3, status: completed)
Conditions: autism
ICD codes: Z13.41
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between ages of 12 and 21 years

          -  Tanner Sage III or IV (post-pubertal)

          -  Diagnostic and Statistical Manual Fourth Edition Text-Revised (DSM-IV-TR) diagnosis of
             autism

          -  Outpatient

          -  Ability to swallow pills

          -  Antipsychotic medication-free for at least 2 weeks

          -  Score of 4 or more on the Clinical Global Impressions Severity Scale

          -  Score of 18 or higher on the Aberrant Behavior Checklist Irritability Scale

          -  Mental age of 18 months or greater based on testing

          -  Subjects must be in good physical health

        Exclusion Criteria:

          -  Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise Specified (PDD
             NOS), Rett's Disorder, childhood disintegrative disorder, schizophrenia, bipolar
             disorder, Fragile X Syndrome, Tuberous Sclerosis

          -  A significant medical condition

          -  An active seizure disorder

          -  Females who are pregnant

          -  Evidence of a prior adequate trial of paliperidone ER

          -  History of neuroleptic malignant syndrome

          -  Hypersensitivity to paliperidone ER
Clinical trial NCT00535405 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: atorvastatin 10 mg, ezetimibe 10 mg/simvastatin 20 mg, atorvastatin 20 mg, ezetimibe 10 mg/simvastatin 40 mg, atorvastatin 40 mg
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has a cholesterol level of 130 mg/dL or greater

          -  Patient is willing to maintain a cholesterol lowering diet for as long as they are in
             the study

          -  Patient is at moderate high risk or high risk for coronary heart disease per the
             National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII)
             guidelines

        Exclusion Criteria:

          -  Patient weighs less than 100 lbs

          -  Patient has an allergy to ezetimibe, simvastatin or atorvastatin
Clinical trial NCT00268216 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: salmeterol 50mcg/ fluticasone propionate 500mcg
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Patients with COPD and FEV1 <60% of predicted normal and baseline (pre-bronchodilator)
             FEV1/FVC ratio <70%.

          -  Current or ex-smokers with a smoking history of at least 10 pack-years.

        Exclusion criteria:

          -  Diagnosis of other respiratory disorders (including asthma).

          -  Requirement for long term oxygen therapy.
Clinical trial NCT00508690 (phase 3, status: completed)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cefmetazole, kanamycin/metronidazole
SMILES: [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O, CC1=NC=C(N1CCO)[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Colorectal tumor(cancer, adenoma and suspected cases) with planned elective
             laparoscopic colorectal resection

        Exclusion Criteria:

          -  ECOG Performance Status >=2

          -  Age<20

          -  Any organ dysfunction

          -  Ileus

          -  Preoperative infectious disease

          -  Antibiotic administration before surgery

          -  Steroid administration before surgery

          -  Neo-adjuvant radiation and/or chemo therapy

          -  Severe diabetes mellitus

          -  Pregnancy/lactational woman

          -  Severe allergy
Clinical trial NCT00413920 (phase 3, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: enteric-coated mycophenolate sodium (ec-mps), prednisone
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Primary donor kidney transplant

          -  Panel reactive antibody (PRA) ≤ 20%

        Exclusion Criteria:

          -  Multi-organ transplantation including dual kidneys or previous transplant with any
             other organ different from kidney

          -  Non-heart beating donor or kidney from a non-compatible donor

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00505687 (phase 3, status: completed)
Conditions: idiopathic parkinson's disease
ICD codes: G20
Drugs: rotigotine
SMILES: CCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who have completed treatment in one of the SP824 (NCT00242008), SP825
             (NCT00243971), or SP826 (NCT00243945) trials

        Exclusion Criteria:

          -  Subjects who had an ongoing serious adverse event from the previous OLE trial that was
             assessed as related to study medication
Clinical trial NCT00050336 (phase 3, status: terminated)
Conditions: carcinoma, non-small-cell lung, metastases, neoplasm
ICD codes: D02.20, D02.21, D02.22, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: lonafarnib (sarasar)
SMILES: NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2C3=C(CCC4=C2C(Br)=CC(Cl)=C4)C=C(Br)C=N3)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female

          -  Histologically or cytologically 3b or 4 (metastatic) non-small cell lung cancer.
             Patients must meet any subcriteria as detailed in the protocol.

          -  Age greater than or equal to 18 years old

          -  ECOG performance status of 0 to 1

          -  Prior diagnosis of brain metastases from NSCLC eligible provided that the brain
             metastases have been adequately treated, patient is neurologically stable and no new
             or progressive brain metastases identified.

          -  Meets protocol requirements for specified laboratory values

          -  Written informed consent

          -  Appropriate use of effective contraception if of childbearing potential

          -  Prior basal cell carcinoma or carcinoma in-situ of the cervix are eligible provided
             they have been treated with no evidence of disease

        Exclusion Criteria:

          -  Prior chemotherapy for any stage of NSCLC

          -  Prior surgery or radiation therapy within the last 2 weeks or incomplete recovery from
             prior procedures or therapy

          -  Concurrent treatment or treatment within the last 2 years for any other malignancy

          -  Grade 2 or greater nausea or Grade 1 or greater vomiting (despite antiemetic
             medication)

          -  Medical conditions that would interfere with taking oral medications

          -  Patients with bone metastases as the only site of disease

          -  Pregnant or nursing women

          -  Known HIV positivity or AIDS-related illness

          -  Patients with significant QTc prolongation at baseline
Clinical trial NCT00333866 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin, pregabalin, pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ACR criteria for fibromyalgia

          -  A score of more or equal to 40 mm on the Pain Visual Analog Scale (VAS) and a an
             average score more or equal to 4 on 4 daily pain diaries

        Exclusion Criteria:

          -  Patients with other severe pain conditions

          -  Patients with severe depression

          -  Patients taking excluded medications